古塞奇尤单抗对活动性银屑病关节炎伴骶髂关节炎患者中轴受累的疗效:DISCOVER-1和DISCOVER-2三期研究的事后分析
该事后分析纳入DISCOVER-1和DISCOVER-2研究中312例影像学确认骶髂关节炎的活动性银屑病关节炎患者,评估古塞奇尤单抗对中轴症状的疗效。结果显示,古塞奇尤单抗每4周或每8周治疗组第24周BASDAI和ASDAS改善均优于安慰剂,且最早第8周出现分离,疗效维持至第52周,与HLA-B27状态无关。
要点
- 古塞奇尤单抗每4周或每8周治疗可显著改善活动性银屑病关节炎伴骶髂关节炎患者的中轴症状。
- 疗效最早在第8周显现,并维持至第52周。
- 疗效不受HLA-B27状态影响。
核心结论
- 在活动性银屑病关节炎伴影像学确认骶髂关节炎的患者中,古塞奇尤单抗每4周或每8周治疗较安慰剂显著改善BASDAI和ASDAS评分。
- 疗效最早第8周出现,并维持至第52周。
- 改善与HLA-B27状态无关。
研究设计与样本
- DISCOVER-1和DISCOVER-2三期研究的事后汇总分析。
- 患者随机接受古塞奇尤单抗100 mg每4周、每8周或安慰剂。
- 分析纳入312例经既往影像学或筛查时骨盆X线确认骶髂关节炎的患者。
主要发现
- 190例评估HLA-B27状态,57例(30%)阳性,133例(70%)阴性。
- 第24周BASDAI50应答率:每4周组36例(38%),每8周组34例(40%),安慰剂组21例(19%);古塞奇尤单抗组达到ASDAS应答的比例高于安慰剂。
临床怎么用
- 对于活动性银屑病关节炎伴影像学确认骶髂关节炎的患者,可考虑使用古塞奇尤单抗每4周或每8周治疗以改善中轴症状。
- 疗效最早第8周显现,临床评估时可关注早期应答。
- HLA-B27状态不影响疗效,阴性患者也可获益。
局限性
- 为事后分析,非预设主要分析。
- 仅纳入影像学确认骶髂关节炎的患者,可能限制普遍性。
- HLA-B27状态仅在部分患者中评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Guselkumab was efficacious in reducing signs and symptoms of psoriatic arthritis in the phase 3 DISCOVER-1 and DISCOVER-2 studies. We aimed to evaluate the efficacy of guselkumab in post-hoc analyses of patients with psoriatic arthritis with imaging-confirmed sacroiliitis consistent with axial involvement. METHODS: In DISCOVER-1, 381 patients with active psoriatic arthritis (defined as ≥3 swollen joints, ≥3 tender joints, and C-reactive protein [CRP] ≥0·3 mg/dL) and in DISCOVER-2, 739 patients with active psoriatic arthritis (defined as ≥5 swollen joints, ≥5 tender joints, and CRP ≥0·6 mg/dL) were randomly allocated to receive guselkumab 100 mg every 4 weeks, guselkumab 100 mg every 8 weeks (week 0, week 4, then every 8 weeks), or placebo. These pooled, post-hoc analyses included patients with axial disease documented by previous imaging or pelvic radiography at screening consistent with sacroiliitis (confirmed by investigator). Efficacy assessments included least squares mean changes, with 95% CIs, in Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) score, modified BASDAI (mBASDAI; excluding peripheral joint pain), spinal pain, and Ankylosing Spondylitis Disease Activity Score (ASDAS), and proportions of patients achieving at least a 50% improvement in BASDAI score (BASDAI50) and achieving ASDAS responses of inactive disease (score <1·3), major improvement (change of ≥2·0), and clinically important improvement (change of ≥1·1). FINDINGS: Of the 1120 patients in the two DISCOVER studies, 312 (28%) were included in this analysis, of whom 118 were in the placebo group, 103 were in the guselkumab every 4 weeks group, and 91 were in the guselkumab every 8 weeks group. 191 (61%) were male, and 121 (39%) were female, and the mean age was 45·1 (SD 11·2). HLA-B27 status was assessed in 190 patients; 57 (30%) were HLA-B27-positive and 133 (70%) were HLA-B27-negative. At week 24, least squares mean changes from baseline in BASDAI were -2·7 (95% CI -3·2 to -2·2) in both guselkumab groups versus -1·3 (-1·8 to -0·9) in the placebo group; similar results were observed for mBASDAI and spinal pain. Least squares mean changes in ASDAS scores at week 24 were -1·4 (95% CI -1·7 to -1·2) in both guselkumab groups and -0·7 (-0·9 to -0·5) for placebo. At week 24, 36 (38%) patients in the guselkumab every 4 weeks group and 34 (40%) of those in the guselkumab every 8 weeks group achieved BASDAI50 versus 21 (19%) of placebo patients; greater proportions of guselkumab-treated patients achieved ASDAS responses versus placebo. Across outcomes, separation from placebo was observed at week 8. Improvements with guselkumab were seen at week 24 independent of HLA-B27 status. These improvements were maintained at week 52 in the guselkumab groups. INTERPRETATION: Patients with active psoriatic arthritis and imaging-confirmed sacroiliitis who were treated with guselkumab every 4 weeks or every 8 weeks had greater mean improvements in BASDAI and ASDAS (as early as week 8) than did placebo-treated participants, with sustained improvements at week 52. FUNDING: Janssen Research & Development LLC.
引用
- Mease PJ, Helliwell PS, Gladman DD, et al. Efficacy of guselkumab on axial involvement in patients with active psoriatic arthritis and sacroiliitis: a post-hoc analysis of the phase 3 DISCOVER-1 and DISCOVER-2 studies. Lancet Rheumatol. 2021. PMID: 38287608. doi:10.1016/S2665-9913(21)00105-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。